Barrett's esophagus: An overrated cancer risk factor

2000 ◽  
Vol 119 (2) ◽  
pp. 587-589 ◽  
Author(s):  
Stuart Jon Spechler
Keyword(s):  
Risk Factor ◽  
Cancer Risk ◽  
Barrett’S Esophagus ◽  
Barrett's Esophagus ◽  
Cancer Risk Factor

Barrett's Esophagus Posed Little Cancer Risk

2011 ◽  
Vol 41 (18) ◽  
pp. 18
Author(s):  
MARY ANN MOON
Keyword(s):  
Cancer Risk ◽  
Barrett’S Esophagus ◽  
Barrett's Esophagus

A STUDY OF THE ACCURACY OF CANCER RISK FACTOR INFORMATION REPORTED TO A CENTRAL REGISTRY COMPARED WITH THAT OBTAINED BY INTERVIEW

1989 ◽  
Vol 129 (3) ◽  
pp. 616-624 ◽  
Author(s):  
ROSS C. BROWNSON ◽  
JAMES R DAVIS ◽  
JIAN C. CHANG ◽  
THOMAS M. DILORENZO ◽  
THOMAS J. KEEFE ◽  
...  
Keyword(s):  
Risk Factor ◽  
Cancer Risk ◽  
Cancer Risk Factor ◽  
Central Registry ◽  
Risk Factor Information

Where is the Truth When It Comes to Cancer Risk in Barrett's Esophagus?

2012 ◽  
Vol 142 (5) ◽  
pp. 1245-1247 ◽  
Author(s):  
Massimiliano di Pietro ◽  
Maria O'Donovan ◽  
Rebecca C. Fitzgerald
Keyword(s):  
Cancer Risk ◽  
Barrett’S Esophagus ◽  
Barrett's Esophagus

Obesity: Barrett’s Esophagus and Esophageal Cancer Risk

2018 ◽  
pp. 39-50
Author(s):  
Jean Marc Chevallier ◽  
Sonja Chiappetta ◽  
Mario Musella
Keyword(s):  
Esophageal Cancer ◽  
Cancer Risk ◽  
Barrett’S Esophagus ◽  
Barrett's Esophagus

scholarly journals Persistent confirmed low-grade dysplasia in Barrett's esophagus is a risk factor for progression to high-grade dysplasia and adenocarcinoma in a US Veterans cohort

2019 ◽  
Author(s):  
K Y Song ◽  
A J Henn ◽  
A A Gravely ◽  
H Mesa ◽  
S Sultan ◽  
...  
Keyword(s):  
Risk Factors ◽  
Risk Factor ◽  
Barrett’S Esophagus ◽  
Barrett's Esophagus ◽  
Independent Risk Factor ◽  
High Grade Dysplasia ◽  
Low Grade ◽  
High Grade ◽  
Increased Risk ◽  
Low Grade Dysplasia

SUMMARY Patients with Barrett's esophagus (BE) and low-grade dysplasia (LGD) are at increased risk of esophageal adenocarcinoma (EAC), although many regress to nondysplastic BE. This has significant clinical importance for patients being considered for endoscopic eradication therapy. Our aim is to determine the risk for progression in patients with confirmed persistent LGD. We performed a single-center retrospective cohort study of patients with BE and confirmed LGD between 2006 and 2016. Confirmed LGD was defined as LGD diagnosed by consensus conference with an expert GI pathologist or review by an expert GI pathologist and persistence as LGD present on subsequent endoscopic biopsy. The primary outcome was the incidence rate of HGD (high-grade dysplasia)/EAC. Secondary outcomes included risk factors for dysplastic progression. Risk factors for progression were assessed using univariate and multivariate analysis with logistic regression. Of 69 patients (mean age 65.2 years) with confirmed LGD were included. In total, 16 of 69 patients (23.2%) with LGD developed HGD/EAC during a median follow-up of 3.74 years (IQR, 1.24–5.45). For persistent confirmed LGD, the rate was 6.44 (95% confidence interval (CI), 2.61–13.40) compared to 2.61 cases per 100 patient-years (95% CI, 0.83–6.30) for nonpersistent LGD. Persistent LGD was found in only 29% of patients. Persistent LGD was an independent risk factor for the development of HGD/EAC (OR 4.18; [95% CI, 1.03–17.1]). Persistent confirmed LGD, present in only 1/3 of patients, was an independent risk factor for the development of HGD/EAC. Persistence LGD may be useful in decision making regarding the management of BE.

Sign in / Sign up

Export Citation Format

Share Document